BIO-RAD LABORATORIES, INC.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
BIO-B$389.98+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In millions, except share data)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| ASSETS · (Unaudited) | ||
| Current assets: | ||
| Cash and cash equivalents | $465.3 | $529.8 |
| Short-term investments | 1,199.0 | 1,010.9 |
| Accounts receivable, less allowance for credit losses of $4.3 and $5.5 as of September 30, 2026 and December 31, 2025, respectively | 422.6 | 460.6 |
| Inventory | 783.9 | 740.7 |
| Prepaid expenses | 160.7 | 136.5 |
| Other current assets | 47.1 | 27.7 |
| Total current assets | 3,078.6 | 2,906.2 |
| Property, plant and equipment, net | 505.7 | 539.9 |
| Operating lease right-of-use assets | 147.1 | 170.0 |
| Goodwill, net | 573.0 | 579.8 |
| Purchased intangibles, net | 104.4 | 174.3 |
| Other investments | 6,273.2 | 6,103.6 |
| Other assets | 101.1 | 102.7 |
| Total assets | $10,783.1 | $10,576.5 |
Condensed Consolidated Balance Sheets
(continued)
(In millions, except share data)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| LIABILITIES AND STOCKHOLDERS’ EQUITY · (Unaudited) | ||
| Current liabilities: | ||
| Accounts payable | $133.5 | $129.0 |
| Accrued payroll and employee benefits | 210.3 | 172.3 |
| Current maturities of long-term debt and notes payable | 400.9 | 1.3 |
| Income and other taxes payable | 37.8 | 36.6 |
| Current operating lease liabilities | 31.8 | 36.1 |
| Other current liabilities | 154.8 | 141.7 |
| Total current liabilities | 969.1 | 517.0 |
| Long-term debt, net of current maturities | 803.1 | 1,201.7 |
| Deferred income taxes | 1,089.4 | 1,059.4 |
| Operating lease liabilities | 127.6 | 145.7 |
| Other long-term liabilities | 190.9 | 199.1 |
| Total liabilities | 3,180.1 | 3,122.9 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value, 7,500,000 shares authorized; issued and outstanding - none | — | — |
| Class A common stock, $0.0001 par value; 80,000,000 shares authorized; shares issued - 25,205,055 and 25,199,760 as of September 30, 2026 and December 31, 2025, respectively; shares outstanding - 21,830,094 and 21,924,284 as of September 30, 2026 and December 31, 2025, respectively | — | — |
| Class B common stock, $0.0001 par value; 20,000,000 shares authorized; shares issued and outstanding - 5,060,815 as of September 30, 2026 and 5,066,110 as of December 31, 2025, respectively | — | — |
| Additional paid-in capital | 470.1 | 476.0 |
| Class A treasury stock at cost, 3,374,961 and 3,275,476 shares as of September 30, 2026 and December 31, 2025, respectively | (1,031.0) | (1,009.6) |
| Retained earnings | 8,479.2 | 8,176.3 |
| Accumulated other comprehensive income (loss) | (315.3) | (189.1) |
| Total stockholders’ equity | 7,603.0 | 7,453.6 |
| Total liabilities and stockholders’ equity | $10,783.1 | $10,576.5 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.